trending Market Intelligence /marketintelligence/en/news-insights/trending/69ggHsRLVFcNHgA_MfGGmA2 content esgSubNav
In This List

XTL Biopharmaceuticals regains compliance with Nasdaq listing rule

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022

Blog

Insight Weekly: CEO pay jumps; yield curve inversion deepens; wind giants lift turbine prices


XTL Biopharmaceuticals regains compliance with Nasdaq listing rule

XTL Biopharmaceuticals Ltd. regained compliance with the minimum $2.5 million stockholders' equity requirement for continued listing on the Nasdaq Capital Market.

Nasdaq determined that the company is compliant with the listing rule after XTL showed that it had stockholders' equity of about $3.6 million as of Sept. 30.